Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer DOI
Lova Sun, Danielle Candelieri-Surette, Tori Anglin-Foote

и другие.

JAMA Otolaryngology–Head & Neck Surgery, Год журнала: 2022, Номер 148(11), С. 1022 - 1022

Опубликована: Сен. 22, 2022

Importance Cetuximab-based and carboplatin-based chemoradiotherapy (CRT) are often used for patients with locally advanced head neck cancer who ineligible cisplatin. There no prospective head-to-head data comparing cetuximab-based regimens radiosensitization. Objective To compare survival CRT in squamous cell carcinoma (HNSCC). Design, Setting, Participants This cohort study included US veterans received a diagnosis of HNSCC between January 2006 December 2020 were treated systemic therapy radiation. Data cutoff was March 1, 2022 analysis conducted from April-May 2022. Exposures Cisplatin, cetuximab, or as captured VA medication registry. Main Outcomes Measures Overall by estimated using Kaplan-Meier methods. We propensity score inverse probability weighting to achieve covariate balance cetuximab-treated carboplatin-treated Cox regression estimate cause-specific hazard ratios death associated carboplatin vs cetuximab. also performed subgroup analyses oropharynx nonoropharynx primary sites. Results A total 8290 (median [IQR] age, 63 [58-68] years; 8201 men [98.9%]; 1225 [15.8%] Black African American 6424 [82.6%] White individuals) nonmetastatic cisplatin (5566 [67%]), (1231 [15%]), cetuximab (1493 [18%]). Compared cisplatin-treated patients, older worse performance status scores higher comorbidity burden. Median (IQR) overall 74.4 (22.3-162.2) months radiotherapy (RT), 43.4 (15.3-123.8) RT, 31.1 (12.4-87.8) RT. After weighting, improved compared (cause-specific ratio, 0.85; 95% CI, 0.78-0.93; P = .001). difference prominent the subgroup. Conclusions Relevance In this veteran population undergoing treatment CRT, almost third receive matching, 15% improvement suggesting that may be preferred radiosensitizer, particularly cancers.

Язык: Английский

Changing Landscape of Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma Treatment and Survival Trends in Thailand: A 13-Year Multicenter Retrospective Study of Patients DOI Creative Commons
Nuttapong Ngamphaiboon, Arunee Dechaphunkul, Chanida Vinayanuwattikun

и другие.

JCO Global Oncology, Год журнала: 2025, Номер 11

Опубликована: Янв. 1, 2025

PURPOSE The incidence and survival rates of head neck squamous cell carcinoma (HNSCC) nasopharyngeal (NPC) vary globally, influenced by factors such as ethnicity, lifestyle, health care systems. METHODS A retrospective analysis was conducted on patients with HNSCC treated between 2008 2020 in four major Thai academic cancer centers, using a multidisciplinary multicenter database. study focused the evolution patient characteristics, changes, treatment landscape alterations over time. RESULTS Among 6,319 patients, most common primary sites were nasopharynx (33%), oral cavity (23%), oropharynx (17%), larynx (15%), hypopharynx (8%). An increase human papillomavirus–related oropharyngeal noted, from 13% to 42% 2019-2020. majority presented locally advanced (LA) stages (IVa/b: 50%, III: 26%). Chemoradiotherapy (54%) surgery (24%) main treatments, cisplatin (79%) being commonly used chemoradiation. Overall (OS) improved annually across all subsites, correlating an intensity-modulated radiotherapy (IMRT) use, 25% 90% median follow-up duration 4.59 years, minimum 2.75 years. Patients IMRT had significantly longer OS compared those non-IMRT techniques, both NPC non-NPC ( P < .001). CONCLUSION To our knowledge, this is largest Thailand that demonstrates increasing outcomes NPC, despite presenting LA stages. use may be contributing patients.

Язык: Английский

Процитировано

1
Impact of HIV on HPV-related cancers in men who have sex with men: a review DOI Creative Commons
Zixuan Zhang,

Yuying Xing,

Tao Gong

и другие.

Frontiers in Cellular and Infection Microbiology, Год журнала: 2025, Номер 14

Опубликована: Янв. 20, 2025

Co-infection with human immunodeficiency virus (HIV) significantly increases the incidence of papillomavirus (HPV) infection and HPV-related cancers among men who have sex (MSM). Conversely, HPV can also influence HIV acquisition rates. HIV-induced immune suppression may affect chromosomal stability, gene expression, protein function other molecular components in MSM cancers. Additionally, alters cellular mechanisms by compromising responses epithelial integrity. In this review, we reviewed on specific MSM, including oropharyngeal squamous cell carcinoma, penile cancer, anal cancer. We integrated epidemiological data from past five years discussed diagnosis treatment strategies. Overall, our review offers crucial insights into underlying these co-infection patients. Our aims to assist future research developing effective strategies for HIV/HPV co-infection.

Язык: Английский

Процитировано

1
Return to Work Up to 5 Years After the End of Treatment Among Patients With Head and Neck Cancer DOI
Femke Jansen, Simone E. J. Eerenstein, Sam Arman

и другие.

JAMA Otolaryngology–Head & Neck Surgery, Год журнала: 2025, Номер unknown

Опубликована: Фев. 6, 2025

Importance Adverse effects of cancer and its treatment may hamper return to work (RTW) among patients with head neck (HNC). Objectives To investigate RTW HNC from end 5 years after associations sociodemographic, clinical, work-related, personal, lifestyle, physical, psychological factors cancer-related symptoms. Design, Setting Participants This prospective, longitudinal, multicenter cohort study used data the Netherlands Quality Life Biomedical cohort. focused on younger than 65 (with a subanalysis 60 years) time diagnosis (March 2014 June 2018) (January 2019 July 2023). Data analysis occurred April 2023 August 2024. Exposure Standard clinical care. Main Outcomes Measures Work status was measured at 3 6 months, 1, 2, 3, 4, using an adjusted version Productivity Cost Questionnaire. Cox regression analyses were performed (baseline, months) associated RTW. Results A total 184 (mean [SD] age, 55.4 [7.0] years; 146 men [79%]) included 77 (42%) had oropharyngeal cancer. increased 26% (42 160 individuals) months 65% (89 137 1 year, which it reduced 52% (51 98 years. At treatment, additional 28 participants (29%) retired. Minor surgery (vs major surgery) faster onwards (hazard ratio [HR], 2.73; 95% CI, 1.17-6.37). Older age (HR, 0.97; 0.94-0.999) more fatigue 0.99; 0.98-0.995) slower onwards. also 0.96; 0.93-0.998). Among 127 years, 72% (47 treatment. Advanced tumor stage 0.59; 0.39-0.90) 0.98-0.999) in this group. Conclusion relevance found that majority returned within year certain sociodemographic symptoms These results inform provide insight into potential targets, such as fatigue, improve

Язык: Английский

Процитировано

1
Precision therapeutic targets for HPV-positive cancers: an overview and new insights DOI Creative Commons
Yaw‐Bin Huang, Jiayi Wang,

Wenbin Yang

и другие.

Infectious Agents and Cancer, Год журнала: 2025, Номер 20(1)

Опубликована: Март 11, 2025

The increasing incidence and mortality rates of HPV-positive cancers, particularly head neck cancer, in recent years have emphasized the pressing need for more efficacious treatment options. Recent studies elucidated molecular distinctions between HPV-negative which are crucial developing precise effective therapeutic strategies. This review updates most findings on variances evaluates current treatments summarizes emerging frontiers HPV-targeted therapies aimed at interventions against these cancers.

Язык: Английский

Процитировано

1
Cetuximab-Based vs Carboplatin-Based Chemoradiotherapy for Patients With Head and Neck Cancer DOI
Lova Sun, Danielle Candelieri-Surette, Tori Anglin-Foote

и другие.

JAMA Otolaryngology–Head & Neck Surgery, Год журнала: 2022, Номер 148(11), С. 1022 - 1022

Опубликована: Сен. 22, 2022

Importance Cetuximab-based and carboplatin-based chemoradiotherapy (CRT) are often used for patients with locally advanced head neck cancer who ineligible cisplatin. There no prospective head-to-head data comparing cetuximab-based regimens radiosensitization. Objective To compare survival CRT in squamous cell carcinoma (HNSCC). Design, Setting, Participants This cohort study included US veterans received a diagnosis of HNSCC between January 2006 December 2020 were treated systemic therapy radiation. Data cutoff was March 1, 2022 analysis conducted from April-May 2022. Exposures Cisplatin, cetuximab, or as captured VA medication registry. Main Outcomes Measures Overall by estimated using Kaplan-Meier methods. We propensity score inverse probability weighting to achieve covariate balance cetuximab-treated carboplatin-treated Cox regression estimate cause-specific hazard ratios death associated carboplatin vs cetuximab. also performed subgroup analyses oropharynx nonoropharynx primary sites. Results A total 8290 (median [IQR] age, 63 [58-68] years; 8201 men [98.9%]; 1225 [15.8%] Black African American 6424 [82.6%] White individuals) nonmetastatic cisplatin (5566 [67%]), (1231 [15%]), cetuximab (1493 [18%]). Compared cisplatin-treated patients, older worse performance status scores higher comorbidity burden. Median (IQR) overall 74.4 (22.3-162.2) months radiotherapy (RT), 43.4 (15.3-123.8) RT, 31.1 (12.4-87.8) RT. After weighting, improved compared (cause-specific ratio, 0.85; 95% CI, 0.78-0.93; P = .001). difference prominent the subgroup. Conclusions Relevance In this veteran population undergoing treatment CRT, almost third receive matching, 15% improvement suggesting that may be preferred radiosensitizer, particularly cancers.

Язык: Английский

Процитировано

29